|Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity|
CIM Dahlberg, D Sarhan, M Chrobok, AD Duru, E Alici
Frontiers in immunology 6, 605, 2015
|Triticum durum metallothionein isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling|
K Bilecen, UH Ozturk, AD Duru, T Sutlu, MV Petoukhov, DI Svergun, ...
Journal of Biological Chemistry 280 (14), 13701-13711, 2005
|The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment|
K Uttervall, AD Duru, J Lund, J Liwing, G Gahrton, E Holmberg, J Aschan, ...
PLoS One 9 (7), e101819, 2014
|Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice|
P Brodin, T Lakshmikanth, R Mehr, MH Johansson, AD Duru, A Achour, ...
PLoS One 5 (10), e13174, 2010
|Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets|
E Kavak, A Najafov, N Ozturk, T Seker, K Cavusoglu, T Aslan, AD Duru, ...
Cellular signalling 22 (10), 1523-1535, 2010
|Inflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complex|
C Madhurantakam, AD Duru, T Sandalova, JR Webb, A Achour
PLoS One 7 (3), e32805, 2012
|Re‐challenging with anti‐CD38 monotherapy in triple‐refractory multiple myeloma patients is a feasible and safe approach|
E Alici, M Chrobok, J Lund, T Ahmadi, I Khan, AD Duru, H Nahi
British journal of haematology 174 (3), 473-477, 2016
|Unexpected T‐cell recognition of an altered peptide ligand is driven by reversed thermodynamics|
EB Allerbring, AD Duru, H Uchtenhagen, C Madhurantakam, MB Tomek, ...
European journal of immunology 42 (11), 2990-3000, 2012
|The MHC Class I cancer-associated neoepitope Trh4 linked with impaired peptide processing induces a unique noncanonical TCR conformer|
I Hafstrand, EM Doorduijn, AD Duru, J Buratto, CC Oliveira, T Sandalova, ...
The Journal of Immunology 196 (5), 2327-2334, 2016
|Deletion of chromosomal region 8p21 confers resistance to Bortezomib and is associated with upregulated decoy TRAIL receptor expression in patients with multiple myeloma|
AD Duru, T Sutlu, A Wallblom, K Uttervall, J Lund, B Stellan, G Gahrton, ...
PloS one 10 (9), e0138248, 2015
|Autologous peripheral blood mononuclear cells as treatment in refractory acute respiratory distress syndrome|
P Jungebluth, B Holzgraefe, ML Lim, AD Duru, V Lundin, N Heldring, ...
Respiration 90 (6), 481-492, 2015
|The immunogenicity of a proline-substituted altered peptide ligand toward the cancer-associated TEIPP neoepitope Trh4 is unrelated to complex stability|
I Hafstrand, EM Doorduijn, R Sun, A Talyzina, M Sluijter, S Pellegrino, ...
The Journal of Immunology 200 (8), 2860-2868, 2018
|Lipid-based transfection reagents exhibit cryo-induced increase in transfection efficiency|
H Sork, JZ Nordin, JJ Turunen, OPB Wiklander, B Bestas, EM Zaghloul, ...
Molecular Therapy-Nucleic Acids 5, e290, 2016
|Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin|
I Hafstrand, EC Sayitoglu, A Apavaloaei, BJ Josey, R Sun, X Han, ...
Proceedings of the National Academy of Sciences 116 (11), 5055-5060, 2019
|Engineering antigen‐specific NK cell lines against the melanoma‐associated antigen tyrosinase via TCR gene transfer|
A Parlar, EC Sayitoglu, D Ozkazanc, AM Georgoudaki, C Pamukcu, ...
European journal of immunology, 2019
|Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells|
M Chrobok, CIM Dahlberg, EC Sayitoglu, V Beljanski, H Nahi, M Gilljam, ...
Cancers 11 (1), 69, 2019
|Crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity|
I Hafstrand, D Badia-Martinez, BJ Josey, M Norström, J Buratto, ...
PloS one 12 (12), e0189584, 2017
|Lenalidomide versus lenalidomide+ dexamethasone prolonged treatment after second‐line lenalidomide+ dexamethasone induction in multiple myeloma|
J Lund, A Gruber, B Lauri, AD Duru, C Blimark, A Swedin, M Hansson, ...
Cancer medicine 7 (6), 2256-2268, 2018
|Identification and strategic targeting of key anti-viral defense mechanisms in Natural Killer cells|
EC Sayitoglu, D Ozkazanc, A Sarac, A Parlar, E Alici, B Erman, AD Duru, ...
The Journal of Immunology 200 (1 Supplement), 169.19-169.19, 2018
|9th Molecular Immunology & Immunogenetics Congress|
M Elkabets, OZ Novoplansky, M Fury, L Cohen, L Cohen, F Cecchi, ...
Molecular Immunology 2018, 2018